A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2011
10/13/2011	US20110251198 Methods for producing viloxazine salts and novel polymorphs thereof
10/13/2011	US20110251197 Lysosomotropic inhibitors of acid ceramidase
10/13/2011	US20110251196 Modulators of G Protein-Coupled Receptor 88
10/13/2011	US20110251195 Adrb2 gene polymorphism associated with intraocular pressure response to topical beta-blockers
10/13/2011	US20110251194 Antineoplastic derivatives, preparation thereof and therapeutic use thereof
10/13/2011	US20110251193 1,2-benzisothiazolinone and isoindolinone derivatives
10/13/2011	US20110251192 Amide compounds, their pharmaceutical compositions, their preparation method and their uses
10/13/2011	US20110251191 Use of substituted 2, 3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
10/13/2011	US20110251190 Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
10/13/2011	US20110251189 Hypoxia targeted compounds for cancer diagnosis and therapy
10/13/2011	US20110251188 Acenaphtho heterocycle compounds, cyclodextrin inclusion compounds and complexes, and uses in the manufactures of bh3 protein analogue, bcl-2 family protein inhibitors thereof
10/13/2011	US20110251187 Heterocyclic compound
10/13/2011	US20110251186 Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use
10/13/2011	US20110251185 Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents
10/13/2011	US20110251184 Substituted hydroxamic acids and uses thereof
10/13/2011	US20110251183 Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
10/13/2011	US20110251182 Agents and methods for treating ischemic and other diseases
10/13/2011	US20110251181 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
10/13/2011	US20110251180 Pharmaceutical agent comprising quinolone compound
10/13/2011	US20110251179 3,4-DIHYDRO-2H-PYRROLO[1,2-a]PYRAZIN-1-ONE DERIVATIVES
10/13/2011	US20110251177 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
10/13/2011	US20110251176 Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
10/13/2011	US20110251175 Stigmine Conjugates for Substance Use Disorders
10/13/2011	US20110251174 2,4-diamino-pyrimidines as aurora inhibitors
10/13/2011	US20110251173 Chemical compounds
10/13/2011	US20110251172 Purine derivatives for treatment of alzheimer's disease
10/13/2011	US20110251171 Heterocyclic compounds and methods of use
10/13/2011	US20110251170 New polymorphic form of 1-(4--2-ethyl-benzyl)-azetidine-3-carboxylic
10/13/2011	US20110251169 Arylethynyl derivatives
10/13/2011	US20110251168 3-aminopyrrolidine derivatives as modulators of chemokine receptors
10/13/2011	US20110251167 Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
10/13/2011	US20110251166 Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the beta2 adrenergic receptor
10/13/2011	US20110251165 Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the beta2 adrenergic receptor
10/13/2011	US20110251164 Carboxamide Derivatives As Muscarinic Receptor Antagonists
10/13/2011	US20110251163 Transdermal Delivery
10/13/2011	US20110251162 Methods of treatment for mrsa infections
10/13/2011	US20110251160 Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
10/13/2011	US20110251159 Phosphoramidate Alkylator Prodrugs
10/13/2011	US20110251158 Fullerene therapies for inflammation and inhibition of build-up of arterial plaque
10/13/2011	US20110251157 Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid
10/13/2011	US20110251156 Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
10/13/2011	US20110251155 Methods of Using Diacerein as an Adjunctive Therapy for Diabetes
10/13/2011	US20110251154 Sulfated polysaccharide compound and the preparation and use thereof
10/13/2011	US20110251153 Prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria
10/13/2011	US20110251152 Nucleoside phosphoramidates
10/13/2011	US20110251151 Combination compositions for reducing intraocular pressure
10/13/2011	US20110251150 Targeting MicroRNAs For The Treatment Of Liver Cancer
10/13/2011	US20110251149 Methods and low dose regimens for treating red blood cell disorders
10/13/2011	US20110251148 Glycomimetic compounds and methods to inhibit infection by hiv
10/13/2011	US20110251147 Compositions Comprising Quinolone and Methods for Treating or Controlling Infections
10/13/2011	US20110251146 Topical antifungal composition
10/13/2011	US20110251145 Phytoestrogenic Compositions for Preventing or Treating Symptoms Associated with Menopause
10/13/2011	US20110251144 Molecular modulators of the wnt/beta-catenin pathway
10/13/2011	US20110251143 Stable elsamitrucin salt formulations
10/13/2011	US20110251142 Use of triterpenic and anthraquinone glycosides as substances exerting hydragogue activity on mucosa of upper respiratory apparatus for the treatment of the effects resulting from the upper respiratory tract diseases
10/13/2011	US20110251141 Composition for topical treatment of mixed vaginal infections
10/13/2011	US20110251138 Lipoic acid metabolite conjugate: preparation and their therapeutic effect
10/13/2011	US20110251135 Inhibitors of peritoneal seeding of cancer cells
10/13/2011	US20110251134 Combination of (a) a dna toposomerase inhibitor and (b) an iap inhibitor
10/13/2011	US20110251133 Blockade of gamma-secretase activity to promote myelination by oligodendrocytes
10/13/2011	US20110251130 Methods and Compositions for Promoting Bone Growth
10/13/2011	US20110251122 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
10/13/2011	US20110250631 Proteoglycan degrading mutants for treatment of cns
10/13/2011	US20110250300 Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
10/13/2011	US20110250297 Treatment of Hyperproliferative Disorders Using Cardiac Glycosides
10/13/2011	US20110250296 Reverse vitamin k effect via photodynamic oxidation targeted at vascular endothelium, fibrin and blood platelets
10/13/2011	US20110250286 Micro Particles for Oral Delivery in Animals
10/13/2011	US20110250285 Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
10/13/2011	US20110250282 Prolonged Release Formulations Comprising an 2-Oxo-1-Pyrrolidine Derivative
10/13/2011	US20110250281 Fexofenadine Microcapsules and Compositions Containing Them
10/13/2011	US20110250279 Controlled-release composition for producing sustained-release preparation containing udenafil
10/13/2011	US20110250278 Particles containing an opioid receptor antagonist and methods of use
10/13/2011	US20110250277 Modified release compositions comprising tacrolimus
10/13/2011	US20110250276 Cosmetic Composition Containing Acetylated Oligoglucuronans
10/13/2011	US20110250275 Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
10/13/2011	US20110250274 Estriol formulations
10/13/2011	US20110250273 Compositions of proton pump inhibitors, kits and methods of their use to treat diabetes
10/13/2011	US20110250272 Solid, orodispersible and/or dispersible composition, without an excipient of known effect and its process of preparation
10/13/2011	US20110250271 Spaced drug delivery system
10/13/2011	US20110250270 Compositions containing a capillary-active system with application-relevant diffferentiability and their use
10/13/2011	US20110250269 Highly efficient and long-acting slow-release formulation of poorly soluble drugs and preparation method thereof
10/13/2011	US20110250268 Compositions and Methods for Inhibiting Gastric Acid Secretion
10/13/2011	US20110250267 Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions
10/13/2011	US20110250266 Liposomal systems comprising sphingomyelin
10/13/2011	US20110250264 Method for formulating large diameter synthetic membrane vesicles
10/13/2011	US20110250263 Protein and nucleic acid delivery vehicles, components and mechanisms thereof
10/13/2011	US20110250261 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
10/13/2011	US20110250260 Inhibition of brain enzymes inolved in cerebral amyloid angiopathy and macular degeneration
10/13/2011	US20110250259 Method of treating and preventing breast diseases and breast cancer with medicated formula
10/13/2011	US20110250257 Fibrous tissue sealant and method of using same
10/13/2011	US20110250256 Dissolvable Nano Web Porous Film and Method of Preparing the Same
10/13/2011	US20110250255 Drug coated stent with endosome-disrupting conjugate
10/13/2011	US20110250254 Antimicrobial compositions and uses
10/13/2011	US20110250244 Melt-coated pharmaceutical composition with fast release
10/13/2011	US20110250243 Nanoparticle compositions
10/13/2011	US20110250242 Arformoterol and tiotropium compositions and methods for use
10/13/2011	US20110250240 Immune enhancing compositions and methods of use thereof
10/13/2011	US20110250238 System for the colon delivery of drugs subject to enzyme degradation and/or poorly absorbed in the gastrointestinal tract
10/13/2011	US20110250235 Production of a saccharide composition comprising glucans and mannans by alkaline and acid hydrolysis of yeast cells
10/13/2011	US20110250231 Method of using punicic acid to enhance immune response and prevent metabolic disorders

1 ... 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 ... 7860